Zydus Lifesciences Limited (ZYDUSLIFE)
Investor Presentation
Investor Presentation - August 2026
- FY26 revenue $3.02bn; EBITDA $959mn; market cap $11.7bn
- India formulations grew with focus on super specialty and chronic therapies
- North America generics and specialty businesses expanding with strong pipeline
- International markets growing via portfolio expansion and biosimilars
- MedTech advancing in orthopaedics, cardiology, nephrology with acquisitions
- R&D investment steady at ~8% of revenues; pipeline includes NCEs, biosimilars, vaccines
- Saroglitazar NDA priority review; approval expected by Q4FY27
- Strong financials: FY26 revenue INR 271bn, EBITDA margin 24.1%, PAT margin 20.4%
- ESG progress: 37% GHG intensity reduction, 37% renewable energy in FY26
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ZYDUSLIFE — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ZYDUSLIFE to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Zydus Lifesciences Limited
Important.
The summary above is generated automatically from Zydus Lifesciences Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.